DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aerospan (Flunisolide Hemihydrate Inhalation) - Summary



Flunisolide, the active component of AEROSPAN ™ (flunisolide) Inhalation Aerosol, is a corticosteroid.

AEROSPAN Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. AEROSPAN Inhalation Aerosol is also indicated for asthma patients requiring oral corticosteroid therapy, where adding AEROSPAN Inhalation Aerosol may reduce or eliminate the need for oral corticosteroids.

Important Limitations of Use

AEROSPAN Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.

AEROSPAN Inhalation Aerosol is NOT indicated in children less than 6 years of age.

See all Aerospan indications & dosage >>


Media Articles Related to Aerospan (Flunisolide Inhalation)

High Physical Activity Tied to Poor Asthma Control in Females
Source: Medscape Allergy & Clinical Immunology Headlines [2015.11.20]
The link was not found in boys and young men. Findings suggested a need for extra attention in asthma treatment for highly active girls and young women.
Medscape Medical News

High levels of physical activity may worsen asthma control in young females
Source: Respiratory / Asthma News From Medical News Today [2015.11.19]
Among 526 adolescents and young adults who were asked about their exercise habits, those with asthma tended to report more physical activity than those without asthma.

Asthma: No Clear Winners in Combination Treatment in Blacks
Source: Medscape Allergy & Clinical Immunology Headlines [2015.11.18]
A randomized trial showed no benefit to long-acting beta-agonists over tiotropium in combination with inhaled corticosteroid for improving outcomes in black adults with asthma.
Medscape Medical News

Emergency Visit for Asthma Predicts Future Acute Care
Source: Medscape Allergy & Clinical Immunology Headlines [2015.11.17]
Children who have made at least one acute-care visit to the emergency department for asthma are at risk for future visits, and might benefit from specialist care, a new study suggests.
Medscape Medical News

Asthma in Children
Source: MedicineNet Allergy Specialty [2015.11.17]
Title: Asthma in Children
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 11/17/2015 12:00:00 AM

more news >>

Published Studies Related to Aerospan (Flunisolide Inhalation)

Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. [2011.10]
BACKGROUND: Inhaled corticosteroids (ICS) are the preferred long-term therapy for subjects with persistent asthma. However, concerns remain about potential effects of long-term ICS use on growth in children. OBJECTIVE: To determine the effect of 1 year of inhalation therapy with flunisolide hydrofluoroalkane (HFA) on growth velocity and bone maturation in children with mild persistent asthma... CONCLUSIONS: In this study, flunisolide HFA did not suppress growth or bone maturation at the highest approved dose for children with persistent asthma. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation...

High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]
The role of inhaled corticosteroids in asthma exacerbation is debated. We compared high doses of nebulized budesonide versus high doses of nebulized flunisolide, in association with a short-acting beta-2-agonist, in the treatment of moderate asthma exacerbation in preschool children... High doses of inhaled flunisolide and budesonide are both effective in the management of moderate asthma exacerbations in pre-school-age children, but the flunisolide therapeutic effect was faster than budesonide.

Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects. [2007.07]
OBJECTIVE: To evaluate the effects of the inhaled flunisolide upon the strength and endurance of the respiratory and peripheral muscles of normal subjects... CONCLUSION: Inhalation of flunisolide by normal subjects for 1 month does not cause any acute or clinically perceived effect in the peripheral or respiratory muscles.

Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]
Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases...

more studies >>

Clinical Trials Related to Aerospan (Flunisolide Inhalation)

Flunisolide HFA in Children With Small Airway Disease [Not yet recruiting]
The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) [Completed]
The objective of this cross-over study is to validate the Preference Module of the EARNS-Q in adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.

Mentored Patient-Oriented Research Career Development Award [Recruiting]
Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung). Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA). Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid. Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy [Completed]
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a typical clinical practice using a retrospective observational cohort study design of large managed care database. Outcomes on interest include asthma related severe exacerbations defined as asthma related emergency department visits, hospitalizations or combined emergency department/hospitalization. Other outcomes of interest include use of albuterol, oral corticosteroids and overall asthma related costs. Outcomes of interest will be compared between the two treatment cohorts (fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids). Dichotomous outcomes (emergency visits, hospitalizations etc) will be compared using Cox regression hazards analysis assessing time to first event for each asthma related endpoint adjusting for differences in baseline demographics such as age, gender, previous asthma medication use, co morbidities, costs, and plan demographics. Total asthma related costs will also be compared using generalized linear models adjusting for baseline differences.

Effect of Physiotherapy on Perceived Health Status in Hospitalized COPD Patients [Recruiting]
Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of patients. Several studies have shown that acute exacerbations (AEs) decrease health-related quality of life, pulmonary function and survival of COPD patients. The objective of the present study is to examine the effects of a physical therapy program on perceived health status in COPD patients hospitalized due to an acute exacerbation.

more trials >>

Page last updated: 2015-11-20

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015